A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium

Annals of Oncology

Volumn 7, Issue 5, 1996, Pages 491-496

  Eckhardt, S G ^a   Burris, H A ^c   Eckardt, J R ^a   Weiss, G ^b   Rodriguez, G ^a   Rothenberg, M ^b   Rinaldi, D ^c   Barrington, R ^b   Kuhn, J G ^b   Masuo, K ^d,e   Sudo, K ^d,e   Atsumi, R ^d,e   Oguma, T ^d,e   Higashi, L ^d,e   Fields, S ^a   Smetzer, L ^a   Von Hoff, D D ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

^b Univ of Texas Health Science Center ^*  (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d Daiichi Pharmaceutical Corporation   (United States)

^e DAIICHI SANKYO CO   (Japan)

Author keywords

Angiogenesis inhibitors; Investigational agents; Sulfated polysaccharides

Indexed keywords

ANGIOGENESIS INHIBITOR; PARACETAMOL; PETHIDINE; TECOGALAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; THROMBOPLASTIN TIME;

EID: 8944249296     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010638     Document Type: Article

References (15)

1. Yanase T, Tamura M, Fujita K et al. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993; 53: 2566-70.
2. Brem H, Gresser I, Grosfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 1993; 28: 1253-7.
3. Gasparini G, Weidner N, Bevilacqua P et al Tumor microvessel density, p53 expression, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454-66.
4. Teicher BA. Angiogenesis and cancer metastasis: Therapeutic approaches. Crit Rev Oncol Hematol 1995; 20: 9-39.
5. Inoue K, Korenaga H, Kadoya S. A sulfated polysaccharide produced by an Arthrobacter species. J Biochem 1982; 92: 1775-84.
6. Inoue K, Kadoya S. The sulfated-polysaccharide-peptidoglycan complex from an Arthrobacter species: Characterization of the linkage between the two components. J Biochem 1983; 94: 189-97.
7. Tecogalan Sodium. Daiichi Pharmaceutical Corporation Investigators Brochure, April 1994.
8. Inoue K, Korenaga H, Tanaka NG et al. The sulfated polysaccharide-peptidoglycan complex potently inhibits embryonic angiogenesis and tumor growth in the presence of cortisone acetate. Carbohydrate Res 1988; 181: 135-42.
9. Tanaka NG, Sakamoto N, Tohgo A et al. Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM). The possibility of a new CAM assay for angiogenesis inhibition. Exp Pathol 1986; 30: 143-50.
10. Nakamura S, Sakurada S, Salahuddin S et al. Inhibition of development of Kaposi's Sarcoma-related lesions by a bacterial cell wall complex. Science 1989; 255: 1437-40.
11. Tanaka NG, Sakamoto N, Inoue K et al. Antitumor effects of an antiangiogenic polysaccharide from an Arthrobacter species with or without steroid. Cancer Res 1989; 49: 6727-30.
12. Folkman J. Clinical applications of research on angiogenesis. NEJM 1995; 333; 1757-63.
13. Tanaka NG, Sakamoto N, Korenaga H et al. The combination of a bacterial polysaccharide and tamoxifen inhibits angiogenesis and tumor growth. Int J Radiat Biol 1991; 60: 79-83.
14. Nguyen M, Watanabe H, Budson AE et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-61.
15. Pluda JM, Shay LE, Foli A et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposis Sarcoma. J Natl Cancer Inst 1993; 85: 1585-92.